Zevra Therapeutics, Inc. ZVRA Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Zevra Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s return on equity?
- Zevra Therapeutics, Inc. (ZVRA) reported return on equity of 100.7% in Q1 2026.
- How has Zevra Therapeutics, Inc.'s return on equity changed year-over-year?
- Zevra Therapeutics, Inc.'s return on equity increased by 149.2% year-over-year, from -204.8% to 100.7%.
- What is the long-term trend for Zevra Therapeutics, Inc.'s return on equity?
- Over 2 years (2023 to 2025), Zevra Therapeutics, Inc.'s return on equity has grown at a 12.9% compound annual growth rate (CAGR), from -67.2% to 85.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.